BiotechTube

Nilotinib + Ruxolitinib

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Phase Chronic Myeloid Leukemia

Conditions

Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, Resistant to Tyrosine Kinase Inhibitor Therapy

Trial Timeline

Aug 1, 2013 → Dec 31, 2018

NCT ID
NCT01914484

About Nilotinib + Ruxolitinib

Nilotinib + Ruxolitinib is a phase 1/2 stage product being developed by Novartis for Chronic Phase Chronic Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01914484. Target conditions include Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Phase Chronic Myeloid Leukemia were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02253277Phase 1Completed
NCT01914484Phase 1/2Completed

Competing Products

20 competing products in Chronic Phase Chronic Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25